/Bio-Techne%20Corp%20sign-by%20JHVEPhoto%20via%20Shutterstock.jpg)
Minneapolis, Minnesota-based Bio-Techne Corporation (TECH) develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company has a market cap of $9 billion and operates through two segments: Protein Sciences, Diagnostics and Spatial Biology.
TECH is expected to release its Q3 2026 earnings on Wednesday, May 6, before the market opens. Ahead of the event, analysts expect the company’s EPS to be $0.48 on a diluted basis, down 4% from $0.50 in the year-ago quarter. The company has met or exceeded Wall Street’s EPS estimates in each of its last four quarters.